Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
AstraZeneca
Harvard Business School
Medtronic
Mallinckrodt

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

AMYVID Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Amyvid patents expire, and when can generic versions of Amyvid launch?

Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.

Summary for AMYVID
International Patents:46
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 3
Clinical Trials: 35
DailyMed Link:AMYVID at DailyMed
Drug patent expirations by year for AMYVID
Generic Entry Opportunity Date for AMYVID
Generic Entry Date for AMYVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AMYVID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Elisa KonofagouN/A
National Institute on Aging (NIA)N/A
University of California, IrvinePhase 3

See all AMYVID clinical trials

Pharmacology for AMYVID
Synonyms for AMYVID
[18F]Florbetapir
18F-AV-45
18F-AV45
18FAV45
4-((1E)-2-(6-{2-(2-(2-(18F)fluoroethoxy)ethoxy)ethoxy}pyridin-3-yl)ethenyl)-N- methylbenzenamine
4-(2-(6-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzamide
4-[(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl]-N-methylaniline
4-{(E)-2-[6-(2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline
4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline
6W15Z5R0RU
956103-76-7
Amyvid (TN)
AV-45
AV-45 compound
Benzenamine, 4-((1E)-2-(6-(2-(2-(2-(fluoro-18F)ethoxy)ethoxy)ethoxy)-3- pyridinyl)ethenyl)-N- methyl-
CHEBI:66880
CHEMBL1774461
D09617
DB09149
DTXSID80241898
Florbetapir
florbetapir (18F)
Florbetapir (18F) [INN]
Florbetapir F 18
Florbetapir F-18
Florbetapir F-18 (USAN)
Florbetapir F-18 [USAN:INN]
florbetapir F18
florbetapir-fluorine-18
GTPL7344
Pet AV-45
SCHEMBL14826096
UNII-6W15Z5R0RU
YNDIAUKFXKEXSV-CRYLGTRXSA-N

US Patents and Regulatory Information for AMYVID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for AMYVID

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1999109 34/2013 Austria   Start Trial PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 2013/028 Ireland   Start Trial PRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 13C0034 France   Start Trial PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Mallinckrodt
McKesson
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.